Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices 82907 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR section Number of 

respondents 

Number of 

responses 

per 

respondent 

Total 

annual 

responses 

Average 

burden 

per response 

Total 

hours 

§ 58.35(b)(7); Quality assurance unit ................................... 300 60.25 18,075 1 18,075 

§ 58.185; Reporting of nonclinical laboratory study results 300 60.25 18,075 27.65 499,774 

Total .............................................................................. ........................ ........................ ........................ ........................ 517,849 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN1

21 CFR section Number of 

recordkeepers 

Number of 

records per 

recordkeeper 

Total 

annual 

records 

Average 

burden 

per recordkeeping 

Total 

hours 

§ 58.29(b); Personnel .................................................. 300 20 6,000 .21 (13 minutes) ..... 1,260 

§ 58.35(b)(1)–(6), and (c); Quality assurance unit ...... 300 270.76 81,228 3.36 ........................ 272,926 

§ 58.63(b) and (c); Maintenance and calibration of 

equipment.

300 60 18,000 .09 (5 minutes) ...... 1,620 

§ 58.81(a)–(c); SOPs ................................................... 300 301.80 90,540 .14 (8 minutes) ...... 12,676 

§ 58.90(c) and (g); Animal care ................................... 300 62.70 18,810 .13 (8 minutes) ...... 2,445 

§ 58.105(a) and (b); Test and control article characterization.300 5 1,500 11.8 ........................ 17,700 

§ 58.107(d); Test and control article handling ............. 300 1 300 4.25 ........................ 1,275 

§ 58.113(a); Mixtures of articles with carriers ............. 300 15.33 4,599 6.8 .......................... 31,273 

§ 58.120; Protocol ........................................................ 300 15.38 4,614 32.7 ........................ 150,878 

§ 58.195; Retention of records .................................... 300 251.50 75,450 3.9 .......................... 294,255 

Total ...................................................................... ........................ ........................ ........................ ................................ 786,308 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Based on an evaluation of the 

information collection, we are retaining 

the currently approved estimates. Our 

assumptions made regarding the time 

needed for the respective activities is 

based on our experience with the 

information collection and informal 

communications with respondents. 

Dated: November 21, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–26044 Filed 11–24–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Declaration Under the Public 

Readiness and Emergency 

Preparedness Act for 

Countermeasures Against Ebolavirus 

and/or Ebola Disease and 

Marburgvirus and/or Marburg Disease 

ACTION: Notice of amendment. 

SUMMARY: The Secretary issues this 

amendment pursuant to section 319F–3 

of the Public Health Service Act to 

amend the Declaration for 

Countermeasures against Marburgvirus 

and/or Marburg Disease to cover both 

Ebolaviruses and Marburgviruses and 

republishes the declaration, as 

amended. The amended republished 

Declaration clarifies that the disease 

threat includes Ebolaviruses and 

Marburgviruses, updates the title of the 

Declaration, expands the Covered 

Countermeasures, and extends the 

effective time period. 

DATES: The amendment is effective as of 

January 1, 2024. 

FOR FURTHER INFORMATION CONTACT: L. 

Paige Ezernack, Office of the Assistant 

Secretary for Preparedness and 

Response, Office of the Secretary, U.S. 

Department of Health and Human 

Services, 200 Independence Avenue 

SW, Washington, DC 20201; 202–260– 

0365, PREPAct@hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Public Readiness and Emergency 

Preparedness Act (PREP Act) authorizes 

the Secretary of the U.S. Department of 

Health and Human Services (the HHS 

Secretary) to issue a Declaration to 

provide liability immunity to certain 

individuals and entities (Covered 

Persons) against any claim of loss 

caused by, arising out of, relating to, or 

resulting from the manufacture, 

distribution, administration, or use of 

medical countermeasures (Covered 

Countermeasures), except for claims 

involving ‘‘willful misconduct’’ as 

defined in the PREP Act. Under the 

PREP Act, a Declaration may be 

amended as circumstances warrant. 

The PREP Act was enacted on 

December 30, 2005, as Public Law 109– 

148, Division C, 2. It amended the 

Public Health Service (PHS) Act, adding 

section 319F–3, which addresses 

liability immunity, and section 319F–4, 

which creates a compensation program. 

These sections are codified at 42 U.S.C. 

247d–6d and 42 U.S.C. 247d–6e, 

respectively. Section 319F–3 of the PHS 

Act has been amended by the Pandemic 

and All-Hazards Preparedness 

Reauthorization Act (PAHPRA), Public 

Law 113–5, enacted on March 13, 2013, 

and the Coronavirus Aid, Relief, and 

Economic Security (CARES) Act, Public 

Law 116–136, enacted on March 27, 

2020, to expand Covered 

Countermeasures under the PREP Act. 

The PREP Act Declaration for 

Countermeasures Against Marburgvirus 

and/or Marburg Disease was first issued 

effective November 25, 2020. (85 FR 

79198 (December 9, 2020)). The PREP 

Act Declaration for Ebola Virus Disease 

Vaccines was first issued December 3, 

2014 (79 FR 73315 (Dec.10, 2014)), and 

amended December 3, 2015 (80 FR 

76541 (Dec. 9, 2015)), December 3, 2016 

(81 FR 89471 (Dec. 12, 2016)), and 

December 1, 2018 (84 FR 764 (Jan. 31, 

2019)). The Declaration for Ebola Virus 


khammond on DSKJM1Z7X2PROD with NOTICES
82908 Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices 

1See https://aspr.hhs.gov/legal/PREPact/Pages/ 

default.aspx. 

2See https://www.ncbi.nlm.nih.gov/pmc/articles/ 

PMC6637750/. 

Disease Therapeutics was issued 

effective February 27, 2015 (80 FR 

22534 (April 22, 2015)), and amended 

February 27, 2015 (80 FR 76536 

(December 9, 2015)), and December 1, 

2018 (84 FR 757 (January 31, 2019)). 

I am extending PREP Act Coverage for 

both Ebolaviruses and Marburgviruses 

due to the continued national security 

threat posed by these viruses. 

Ebolaviruses and Marburgviruses have 

the potential to cause significant 

morbidity and mortality during 

outbreaks. The risk of domestic cases is 

high due to ongoing outbreaks in other 

countries over the past decade. 

Development of and stockpiling 

vaccines, therapeutics, devices, and 

diagnostics for all species of both 

Ebolaviruses and Marburgviruses is 

needed for continued U.S. preparedness 

against the credible threat of a public 

health emergency due to outbreaks of 

these viruses. 

I am amending the PREP Act 

Declaration for Countermeasures 

Against Marburgvirus and/or Marburg 

Disease to cover countermeasures 

previously covered under the 

Declaration for Ebola Virus Disease 

Vaccines and the Declaration for Ebola 

Virus Disease Therapeutics due to the 

similarities of the viruses and the need 

to expand Covered Countermeasures 

against Ebola Disease to include all 

vaccines, diagnostics, and devices in 

addition to previously covered vaccines 

and therapeutics, and to cover these 

countermeasures when administered or 

used by an Authority Having 

Jurisdiction to respond to a declared 

emergency, in addition to previously 

covered activities directly supported by 

the United States. All previously 

Covered Countermeasures for 

Ebolavirus and distribution activities 

continue to be covered. This action has 

the effect of combining the three 

previous Declarations into one amended 

Declaration and makes PREP Act 

coverage for Ebolavirus 

countermeasures consistent with PREP 

Act coverage provided for other health 

threats, including Marburg, Smallpox, 

Pandemic Influenza, Anthrax, and 

Acute Radiation Syndrome and 

emerging infectious diseases such as 

COVID–19.1 This amended Declaration 

for Countermeasures Against Ebolavirus 

and/or Ebola Disease and Marburgvirus 

and/or Marburg Disease supersedes the 

PREP Act Declaration for Ebola Virus 

Disease Vaccines and the PREP Act 

Declaration for Ebola Virus Disease 

Therapeutics. The Declarations for 

Ebola Virus Disease Vaccines and Ebola 

Virus Disease Therapeutics will expire 

under their own terms on December 31, 

2023 and this amended Declaration 

becomes effective January 1, 2024, 

effectively replacing the three prior 

Declarations. 

To be consistent with the most 

current World Health Organization 

International Classification of Diseases, 

the term Ebola disease or ‘‘EBOD’’ is 

used in this Declaration to refer to the 

disease, health condition, or threat to 

health that constitutes or may constitute 

a public health emergency. The term 

Marburg Disease or ‘‘MARD’’ is used in 

this Declaration to refer to the disease, 

health condition, or threat to health that 

constitutes or may constitute a public 

health emergency.2

Specifically, I am now amending the 

PREP Act Declaration Against 

Marburgvirus and/or Marburg Disease 

Countermeasures to: amend the title of 

the declaration to reflect that it covers 

Ebolaviruses and Marburgviruses; 

update Section I to identify the public 

health threat as arising from 

Ebolaviruses and Marburgviruses; 

update Section VI to amend the 

definition of Covered Countermeasures 

and to extend coverage to all vaccines, 

diagnostics, and devices for Ebolavirus 

in addition to vaccines and 

therapeutics; extend Section VII of the 

Declaration to provide coverage for 

Ebolavirus Countermeasures when 

administered or used by an Authority 

Having Jurisdiction to respond to a 

declared emergency; update Section VIII 

to amend the category of disease to be 

inclusive of Ebolaviruses and 

Marburgviruses; extend in Section XII 

the effective time period of the 

declaration through December 31, 2028; 

and republish the declaration in its 

entirety, as amended. 

Unless otherwise noted, all statutory 

citations below are to the U.S. Code. 

Description of This Amendment by 

Section 

I am now amending the title of the 

Declaration to ‘‘Declaration, as 

Amended, for Public Readiness and 

Emergency Preparedness Act Coverage 

for Countermeasures against 

Ebolaviruses and/or Ebola Disease and 

Marburgvirus and/or Marburg Disease.’’ 

Section I. Determination of Public 

Health Emergency or Credible Risk of 

Future Public Health Emergency 

I am amending Section I of the 

Declaration to update the determination 

of a public health emergency to state 

that the spread of Ebolaviruses and 

Marburgviruses, and any resulting 

diseases or conditions including EBOD 

and MARD, and any virus or disease 

subcategories of these, presents a 

credible risk of a future public health 

emergency. Continued coverage under 

the PREP Act, as provided in this 

Declaration, is intended to prepare for 

and mitigate that credible risk. 

Section VI. Covered Countermeasures 

I am amending Section VI of the 

Declaration to include any antiviral, any 

other drug, any biologic, any diagnostic, 

any other device, or any vaccine, used 

to diagnose, mitigate, prevent, treat, 

cure, or limit EBOD, MARD, or the 

transmission of Ebolaviruses, 

Marburgviruses, or a virus mutating 

therefrom, or any device used in the 

administration of any such product, and 

all components and constituent 

materials of any such product. 

Section VIII. Category of Disease, 

Health Condition, or Threat 

I am amending Section VIII of the 

Declaration to update the category of 

disease to include any diseases or 

conditions including EBOD and MARD 

caused by Ebolaviruses and 

Marburgviruses, or any virus or disease 

subcategories of these or virus mutating 

therefrom. 

Section XII. Effective Time Period 

I am extending the effective time 

period for the Declaration through 

December 31, 2028. 

Other conforming changes and 

technical corrections may be made 

throughout the Declaration for 

consistency and clarity. 

Declaration, as Amended, for Public 

Readiness and Emergency Preparedness 

Act Coverage for Countermeasures 

Against Ebolavirus and/or Ebola Disease 

and Marburgvirus and/or Marburg 

Disease 

To the extent any term previously 

included in the Declaration for 

Countermeasures Against Marburgvirus 

and/or Marburg Disease, the Declaration 

for Vaccines Against Ebola Virus 

Disease, or the Declaration for 

Therapeutics Against Ebola Virus 

Disease, including amendments, are 

inconsistent with any provision of this 

Republished Declaration, the terms of 

this Republished Declaration are 

controlling. 

I. Determination of Public Health 

Emergency 

42 U.S.C. 247d–6d(b)(1) 

I have determined that there is a 

credible risk that the spread of 

Ebolaviruses and Marburgviruses, and 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices 82909 

any resulting diseases or conditions 

including Ebola Disease (EBOD) and 

Marburg Disease (MARD), and any virus 

or disease subcategories of these may in 

the future constitute a public health 

emergency. For the purposes of this 

Declaration, MARD is the illness 

resulting from infection by any virus of 

the Orthomarburgvirus genus. EBOD is 

the illness resulting from infection of 

any of the following virus species of the 

Orthoebolavirus genus: 

• Bundibugyo virus 

• Ebola virus 

• Sudan virus 

• Taı ̈ Forest virus 

• Ebolaviruses with undefined 

pathogenicity in humans 

II. Factors Considered 

42 U.S.C. 247d–6d(b)(6) 

I have considered the desirability of 

encouraging the design, development, 

clinical testing, or investigation, 

manufacture, labeling, distribution, 

formulation, packaging, marketing, 

promotion, sale, purchase, donation, 

dispensing, prescribing, administration, 

licensing, and use of the Covered 

Countermeasures. 

III. Recommended Activities 

42 U.S.C. 247d–6d(b)(1) 

I recommend, under the conditions 

stated in this Declaration, the 

manufacture, testing, development, 

distribution, administration, and use of 

the Covered Countermeasures. 

IV. Liability Immunity 

42 U.S.C. 247d–6d(a), 247d–6d(b)(1) 

Liability immunity as prescribed in 

the PREP Act and conditions stated in 

this Declaration is in effect for the 

Recommended Activities described in 

Section III. 

V. Covered Persons 

42 U.S.C. 247d–6d(i)(2), (3), (4), (6), 

(8)(A) and (B) 

Covered Persons who are afforded 

liability immunity under this 

Declaration are ‘‘manufacturers,’’ 

‘‘distributors,’’ ‘‘program planners,’’ 

‘‘qualified persons,’’ and their officials, 

agents, and employees, as those terms 

are defined in the PREP Act, and the 

United States. In addition, I have 

determined that the following 

additional persons are qualified 

persons: (a) Any person authorized in 

accordance with the public health and 

medical emergency response of the 

Authority Having Jurisdiction, as 

described in Section VII below, to 

prescribe, administer, deliver, distribute 

or dispense the Covered 

Countermeasures, and their officials, 

agents, employees, contractors and 

volunteers, following a Declaration of an 

emergency; (b) any person authorized to 

prescribe, administer, or dispense the 

Covered Countermeasures or who is 

otherwise authorized to perform an 

activity under an Emergency Use 

Authorization in accordance with 

section 564 of the FD&C Act; and (c) any 

person authorized to prescribe, 

administer, or dispense Covered 

Countermeasures in accordance with 

section 564A of the FD&C Act. 

VI. Covered Countermeasures 

42 U.S.C. 247d–6b(c)(1)(B), 42 U.S.C. 

247d–6d(i)(1) and (7) 

Covered Countermeasures are: (1) any 

antiviral, any other drug, any biologic, 

any diagnostic, any other device, or any 

vaccine, used to diagnose, mitigate, 

prevent, treat, cure, or limit the harm 

EBOD, MARD, or the transmission of 

Ebolaviruses, Marburgviruses, or a virus 

mutating therefrom, any device used in 

the administration of any such product, 

and all components and constituent 

materials of any such product; (2) any 

product to diagnose, mitigate, prevent, 

treat, or cure a serious or lifethreatening disease or condition caused 

by a product described in clause (1); or 

(3) a product or technology intended to 

enhance the use or effect of a drug, 

biological product, or device described 

in clause (1) or (2). 

Covered Countermeasures must be 

‘‘qualified pandemic or epidemic 

products,’’ or ‘‘security 

countermeasures,’’ or drugs, biological 

products, or devices authorized for 

investigational or emergency use, as 

those terms are defined in the PREP Act, 

the FD&C Act, and the Public Health 

Service Act. 

VII. Limitations on Distribution 

42 U.S.C. 247d}6d(a)(5) and (b)(2)(E) 

I have determined that liability 

immunity is afforded to Covered 

Persons only for Recommended 

Activities involving Covered 

Countermeasures that are related to: 

(a) Present or future federal contracts, 

cooperative agreements, grants, other 

transactions, interagency agreements, 

memoranda of understanding, or other 

federal agreements, or activities directly 

conducted by the Federal Government; or 

(b) Activities authorized in accordance 

with the public health and medical response 

of the Authority Having Jurisdiction to 

prescribe, administer, deliver, distribute, or 

dispense the Covered Countermeasures 

following a Declaration of an emergency. 

i. The Authority Having Jurisdiction 

means the public agency or its delegate 

that has legal responsibility and 

authority for responding to an incident, 

based on political or geographical (e.g., 

city, county, tribal, state, or federal 

boundary lines) or functional (e.g., law 

enforcement, public health) range or 

sphere of authority. 

ii. A Declaration of emergency means 

any Declaration by any authorized local, 

regional, state, or federal official of an 

emergency specific to events that 

indicate an immediate need to 

administer and use the Covered 

Countermeasures, with the exception of 

a federal Declaration in support of an 

Emergency Use Authorization under 

section 564 of the FD&C Act unless such 

Declaration specifies otherwise. 

I have also determined that, for 

governmental program planners only, 

liability immunity is afforded only to 

the extent such program planners obtain 

Covered Countermeasures through 

voluntary means, such as (1) donation; 

(2) commercial sale; (3) deployment of 

Covered Countermeasures from federal 

stockpiles; or (4) deployment of 

donated, purchased, or otherwise 

voluntarily obtained Covered 

Countermeasures from state, local, or 

private stockpiles. 

VIII. Category of Disease, Health 

Condition, or Threat 

42 U.S.C. 247d–6d(b)(2)(A) 

The category of disease, health 

condition, or threat for which I 

recommend the administration or use of 

the Covered Countermeasures is any 

diseases or conditions including EBOD 

and MARD caused by Ebolaviruses and 

Marburgviruses, or any virus or disease 

subcategories of these or virus mutating 

therefrom. 

IX. Administration of Covered 

Countermeasures 

42 U.S.C. 247d–6d(a)(2)(B) 

Administration of the Covered 

Countermeasure means physical 

provision of the countermeasures to 

recipients, or activities and decisions 

directly relating to public and private 

delivery, distribution and dispensing of 

the countermeasures to recipients, 

management and operation of 

countermeasure programs, or 

management and operation of locations 

for purpose of distributing and 

dispensing countermeasures. 

X. Population 

42 U.S.C. 247d–6d(a)(4), 247d– 

6d(b)(2)(C) 

The populations of individuals 

include any individual who uses or is 

administered the Covered 


khammond on DSKJM1Z7X2PROD with NOTICES
82910 Federal Register / Vol. 88, No. 226 / Monday, November 27, 2023 / Notices 

Countermeasures in accordance with 

this Declaration. 

Liability immunity is afforded to 

manufacturers and distributors without 

regard to whether the countermeasure is 

used by or administered to this 

population; liability immunity is 

afforded to program planners and 

qualified persons when the 

countermeasure is used by or 

administered to this population, or the 

program planner or qualified person 

reasonably could have believed the 

recipient was in this population. 

XI. Geographic Area 

42 U.S.C. 247d–6d(a)(4), 247d– 

6d(b)(2)(D) 

Liability immunity is afforded for the 

administration or use of a Covered 

Countermeasure without geographic 

limitation. 

Liability immunity is afforded to 

manufacturers and distributors without 

regard to whether the countermeasure is 

used by or administered in any 

designated geographic area; liability 

immunity is afforded to program 

planners and qualified persons when 

the countermeasure is used by or 

administered in any designated 

geographic area, or the program planner 

or qualified person reasonably could 

have believed the recipient was in that 

geographic area. 

XII. Effective Time Period 

42 U.S.C. 247d–6d(b)(2)(B) 

Liability immunity for Covered 

Countermeasures through means of 

distribution other than in accordance 

with the public health and medical 

response of the Authority Having 

Jurisdiction and extends through 

December 31, 2028. 

Liability immunity for Covered 

Countermeasures administered and 

used in accordance with the public 

health and medical response of the 

Authority Having Jurisdiction begins 

with a Declaration and lasts through (1) 

the final day the emergency Declaration 

is in effect, or (2) December 31, 2028, 

whichever occurs first. 

XIII. Additional Time Period of 

Coverage 

42 U.S.C. 247d–6d(b)(3)(B) and (C) 

I have determined that an additional 

12 months of liability protection is 

reasonable to allow for the 

manufacturer(s) to arrange for 

disposition of the Covered 

Countermeasure, including return of the 

Covered Countermeasures to the 

manufacturer, and for Covered Persons 

to take such other actions as are 

appropriate to limit the administration 

or use of the Covered Countermeasures. 

Covered Countermeasures obtained 

for the Strategic National Stockpile 

(SNS) during the effective period of this 

Declaration are covered through the date 

of administration or use pursuant to a 

distribution or release from the SNS. 

XIV. Countermeasures Injury 

Compensation Program 

42 U.S.C 247d–6e 

The PREP Act authorizes the 

Countermeasures Injury Compensation 

Program (CICP) to provide benefits to 

certain individuals or estates of 

individuals who sustain a covered 

serious physical injury as the direct 

result of the administration or use of the 

Covered Countermeasures, and benefits 

to certain survivors of individuals who 

die as a direct result of the 

administration or use of the Covered 

Countermeasures. The causal 

connection between the countermeasure 

and the serious physical injury must be 

supported by compelling, reliable, valid, 

medical, and scientific evidence in 

order for the individual to be considered 

for compensation. The CICP is 

administered by the Health Resources 

and Services Administration, within the 

Department of Health and Human 

Services. Information about the CICP is 

available at the toll-free number 1–855– 

266–2427 or http://www.hrsa.gov/cicp/. 

XV. Amendments 

42 U.S.C. 247d–6d(b)(4) 

The December 3, 2014, Declaration 

under the PREP Act for 

Countermeasures Against Ebola Virus 

Disease Vaccines was first published on 

December 10, 2014, and amended and 

republished on December 9, 2015, 

December 12, 2016, and January 31, 

2019. The republished amended 

Declaration for Countermeasures 

Against Ebolavirus and/or Ebola Disease 

and Marburgvirus and/or Marburg 

Disease supersedes the Declaration for 

Countermeasures Against Ebola Virus 

Disease Vaccines. 

The February 27, 2015, Declaration 

under the PREP Act for 

Countermeasures Against Ebola Virus 

Disease Therapeutics was first 

published on April 22, 2015, and 

amended and republished on December 

9, 2015, December 12, 2016, and January 

31, 2019. The republished amended 

Declaration for Countermeasures 

Against Ebolavirus and/or Ebola Disease 

and Marburgvirus and/or Marburg 

Disease supersedes the Declaration for 

Countermeasures Against Ebola Virus 

Disease Therapeutics. 

The November 25, 2020, Declaration 

under the PREP Act for 

Countermeasures Against Marburgvirus 

and/or Marburg Disease was published 

on December 9, 2020. This is the first 

amendment to and republication of the 

Declaration. 

Any further amendments to this 

Declaration will be published in the 

Federal Register, as warranted. 

Authority: 42 U.S.C. 247d–6d. 

Dated: November 21, 2023. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2023–26075 Filed 11–24–23; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Amend Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Heart, Lung, 

and Blood Institute Special Emphasis 

Panel T32 Diversity Training Grants, 

December 1, 2023, 11:00 a.m. to 1:00 

p.m., National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20892 

which was published in the Federal 

Register on October 26, 2023, FR 

Document No. 2023–23751, 88 FRN 

73863. 

This notice is being amended to 

change the meeting title to ‘‘The 

National Heart, Lung, and Blood 

Institute Special Emphasis Panel T32 

Member Conflicts SEP.’’ The meeting is 

closed to the public. 

Dated: November 20, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–26020 Filed 11–24–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Customs Broker Permit User Fee 

Payment for 2024 and Announcement 

of eCBP Portal Payment Option 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This document provides 

notice to customs brokers that the 

annual user fee that is assessed for each 


khammond on DSKJM1Z7X2PROD with NOTICES